Richard van Breemen
Overview
Explore the profile of Richard van Breemen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saldivia N, Heller G, Zelada D, Whitehair J, Venkat N, Konjeti A, et al.
Mol Ther
. 2024 Jun;
32(9):3163-3176.
PMID: 38937968
Galactosyl-ceramidase (GALC) is a ubiquitous lysosomal enzyme crucial for the correct myelination of the mammalian nervous system during early postnatal development. However, the physiological consequence of GALC deficiency in the...
2.
Waidyanatha S, Collins B, Cristy T, Embry M, Gafner S, Johnson H, et al.
Food Chem Toxicol
. 2024 Feb;
186:114537.
PMID: 38417538
Increases in botanical use, encompassing herbal medicines and dietary supplements, have underlined a critical need for an advancement in safety assessment methodologies. However, botanicals present unique challenges for safety assessment...
3.
Rebiai R, Rue E, Zaldua S, Nguyen D, Scesa G, Jastrzebski M, et al.
Front Mol Neurosci
. 2022 May;
15:896314.
PMID: 35620447
Krabbe Disease (KD) is a lysosomal storage disorder characterized by the genetic deficiency of the lysosomal enzyme β-galactosyl-ceramidase (GALC). Deficit or a reduction in the activity of the GALC enzyme...
4.
Feinstein D, Hafner J, van Breemen R, Rubinstein I
Toxicol Commun
. 2022 Apr;
6(1):28-29.
PMID: 35449825
No abstract available.
5.
Wright E, Hafner J, Podolej G, Feinstein D, van Breemen R, Rubinstein I, et al.
West J Emerg Med
. 2022 Mar;
22(4):1014-1019.
PMID: 35354010
Introduction: Synthetic cannabinoids are a rapidly expanding subset of designer drugs widely available in the United States since 2008. In Illinois during the spring of 2018, over 160 documented cases...
6.
Reiter C, Rebiai R, Kwak A, Marshall J, Wozniak D, Scesa G, et al.
ASN Neuro
. 2022 Mar;
14:17590914221087817.
PMID: 35300522
Psychosine exerts most of its toxic effects by altering membrane dynamics with increased shedding of extracellular vesicles (EVs). In this study, we discovered that a fraction of psychosine produced in...
7.
Rubinstein I, Weinberg G, van Breemen R, Hershow R, Feinstein D
Toxicol Commun
. 2019 Mar;
2(1):59-61.
PMID: 30923779
Poisoning by long acting anti-coagulant rodenticides (LAARs) requires long-term treatment with oral vitamin K1 (VK1). However, discontinuing treatment based on normalization of INR, may leave some patients with serum LAAR...
8.
Feinstein D, Gierzal K, Iqbal A, Kalinin S, Ripper R, Lindeblad M, et al.
Toxicol Lett
. 2019 Feb;
306:61-65.
PMID: 30779948
Brodifacoum (BDF) is a potent, long-acting anticoagulant rodenticide that can cause fatal poisoning in humans. The chemical structure of BDF includes 2 chiral carbons, resulting in 2 pairs of diastereomers,...
9.
Rubinstein I, van Breemen R, Nosal D, Weinberg G, Hershow R, Feinstein D
Drugs R D
. 2019 Jan;
19(1):67-71.
PMID: 30689138
A recent multi-state outbreak of life-threatening bleeding following inhalation of synthetic cannabinoids has been attributed to contamination with the long-acting anticoagulant rodenticide (LAAR) brodifacoum, a second-generation, highly potent, long-acting derivative...
10.
Abdelkarim H, Marshall M, Scesa G, Smith R, Rue E, Marshall J, et al.
Sci Rep
. 2018 Aug;
8(1):12462.
PMID: 30127535
Aggregation of α-synuclein, the hallmark of α-synucleinopathies such as Parkinson's disease, occurs in various glycosphingolipidoses. Although α-synuclein aggregation correlates with deficiencies in the lysosomal degradation of glycosphingolipids (GSL), the mechanism(s)...